Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Wolters, EC; Berendse, HW
   Management of psychosis in Parkinson's disease
   CURRENT OPINION IN NEUROLOGY
   
   E.C. Wolters e H.W. Berendse, "Management of psychosis in Parkinson's disease", CURR OP NEU, 14(4), 2001, pp. 499-504
2. Tauscher, J; Kapur, S
   Choosing the right dose of antipsychotics in schizophrenia - Lessons from neuroimaging studies
   CNS DRUGS
   
   J. Tauscher e S. Kapur, "Choosing the right dose of antipsychotics in schizophrenia - Lessons from neuroimaging studies", CNS DRUGS, 15(9), 2001, pp. 671-678
3. Hughes, DA; Walley, T
   Economic evaluations during early (phase II) drug development - A role forclinical trial simulations?
   PHARMACOECONOMICS
   
   D.A. Hughes e T. Walley, "Economic evaluations during early (phase II) drug development - A role forclinical trial simulations?", PHARMACOECO, 19(11), 2001, pp. 1069-1077
4. Beelen, AP; Yeo, KTJ; Lewis, LD
   Asymptomatic QTc prolongation associated with quetiapine fumarate overdosein a patient being treated with risperidone
   HUMAN & EXPERIMENTAL TOXICOLOGY
   
   A.P. Beelen et al., "Asymptomatic QTc prolongation associated with quetiapine fumarate overdosein a patient being treated with risperidone", HUM EXP TOX, 20(4), 2001, pp. 215-219
5. Rowsell, R; Link, C; Donoghue, J
   Atypical antipsychotics in the treatment of schizophrenia - Validity of dropout rates as proxy measure of tolerability is unknown
   BRITISH MEDICAL JOURNAL
   
   R. Rowsell et al., "Atypical antipsychotics in the treatment of schizophrenia - Validity of dropout rates as proxy measure of tolerability is unknown", BR MED J, 322(7291), 2001, pp. 925-925
6. Gefvert, O; Lundberg, T; Wieselgren, IM; Bergstrom, M; Langstrom, B; Wiesel, FA; Lindstrom, L
   D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study
   EUROPEAN NEUROPSYCHOPHARMACOLOGY
   
   O. Gefvert et al., "D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study", EUR NEUROPS, 11(2), 2001, pp. 105-110
7. Sharma, T
   Quetiapine - efficacy in different domains
   EUROPEAN NEUROPSYCHOPHARMACOLOGY
   
   T. Sharma, "Quetiapine - efficacy in different domains", EUR NEUROPS, 11, 2001, pp. 385-390
8. Kasper, S; Tauscher, J; Heiden, A
   Quetiapine: efficacy and tolerability in schizophrenia
   EUROPEAN NEUROPSYCHOPHARMACOLOGY
   
   S. Kasper et al., "Quetiapine: efficacy and tolerability in schizophrenia", EUR NEUROPS, 11, 2001, pp. 405-413
9. Lynch, J; Morrison, J; Graves, N; Meddis, D; Drummond, MF; Hellewell, JSE
   The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia
   EUROPEAN PSYCHIATRY
   
   J. Lynch et al., "The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia", EUR PSYCHIA, 16(5), 2001, pp. 307-312
10. Sa, DS; Kapur, S; Lang, AE
    Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis
    CLINICAL NEUROPHARMACOLOGY
    
    D.S. Sa et al., "Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis", CLIN NEUROP, 24(4), 2001, pp. 242-244
11. DeVane, CL; Nemeroff, CB
    Clinical pharmacokinetics of quetiapine - An atypical antipsychotic
    CLINICAL PHARMACOKINETICS
    
    C.L. DeVane e C.B. Nemeroff, "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic", CLIN PHARMA, 40(7), 2001, pp. 509-522
12. Binder, EB; Kinkead, B; Owens, MJ; Kilts, CD; Nemeroff, CB
    Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating
    JOURNAL OF NEUROSCIENCE
    
    E.B. Binder et al., "Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating", J NEUROSC, 21(2), 2001, pp. 601-608
13. Sarkar, J; Jones, N; Sullivan, G
    A case of depersonalization-derealization syndrome during treatment with quetiapine
    JOURNAL OF PSYCHOPHARMACOLOGY
    
    J. Sarkar et al., "A case of depersonalization-derealization syndrome during treatment with quetiapine", J PSYCHOPH, 15(3), 2001, pp. 209-211
14. Mir, S; Taylor, D
    Atypical antipsychotics and hyperglycaemia
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    
    S. Mir e D. Taylor, "Atypical antipsychotics and hyperglycaemia", INT CLIN PS, 16(2), 2001, pp. 63-73
15. Wirshing, DA
    Adverse effects of atypical antipsychotics
    JOURNAL OF CLINICAL PSYCHIATRY
    
    D.A. Wirshing, "Adverse effects of atypical antipsychotics", J CLIN PSY, 62, 2001, pp. 7-10
16. Mullen, J; Jibson, MD; Sweitzer, D
    A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study
    CLINICAL THERAPEUTICS
    
    J. Mullen et al., "A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study", CLIN THER, 23(11), 2001, pp. 1839-1854
17. Bymaster, FP; Falcone, JF; Bauzon, D; Kennedy, JS; Schenck, K; DeLapp, NW; Cohen, ML
    Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    F.P. Bymaster et al., "Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine", EUR J PHARM, 430(2-3), 2001, pp. 341-349
18. Woods, SW; Stolar, M; Sernyak, MJ; Charney, DS
    Consistency of atypical antipsychotic superiority to placebo in recent clinical trials
    BIOLOGICAL PSYCHIATRY
    
    S.W. Woods et al., "Consistency of atypical antipsychotic superiority to placebo in recent clinical trials", BIOL PSYCHI, 49(1), 2001, pp. 64-70
19. Ruhe, HG; Becker, HE; Jessurun, P; Marees, CH; Heeringa, M; Vermeulen, HDB
    Agranulocytosis and granulocytopenia associated with quetiapine
    ACTA PSYCHIATRICA SCANDINAVICA
    
    H.G. Ruhe et al., "Agranulocytosis and granulocytopenia associated with quetiapine", ACT PSYC SC, 104(4), 2001, pp. 311-313
20. Jones, HM; Travis, MJ; Mulligan, R; Bressan, RA; Visvikis, D; Gacinovic, S; Ell, PJ; Pilowsky, LS
    In vivo 5-HT2A receptor blockade by quetiapine - An R91150 single photon emission tomography study
    PSYCHOPHARMACOLOGY
    
    H.M. Jones et al., "In vivo 5-HT2A receptor blockade by quetiapine - An R91150 single photon emission tomography study", PSYCHOPHAR, 157(1), 2001, pp. 60-66
21. Brecher, M; Rak, IW; Melvin, K; Jones, AM
    The long-term effect of quetiapine (Seroquel (TM)) monotherapy on weight in patients with schizophrenia
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    
    M. Brecher et al., "The long-term effect of quetiapine (Seroquel (TM)) monotherapy on weight in patients with schizophrenia", INT J PSYC, 4(4), 2000, pp. 287-291
22. Reznik, I; Benatov, R; Sirota, P
    Long-term efficacy and safety of quetiapine in treatment-refractory schizophrenia: A case report
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    
    I. Reznik et al., "Long-term efficacy and safety of quetiapine in treatment-refractory schizophrenia: A case report", INT J PSYC, 4(1), 2000, pp. 77-80
23. Matheson, AJ; Lamb, HM
    Quetiapine - A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease
    CNS DRUGS
    
    A.J. Matheson e H.M. Lamb, "Quetiapine - A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease", CNS DRUGS, 14(2), 2000, pp. 157-172
24. Khouzam, HR
    Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine
    DEPRESSION AND ANXIETY
    
    H.R. Khouzam, "Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine", DEPRESS ANX, 11(2), 2000, pp. 80-82
25. Worrel, JA; Marken, PA; Beckman, SE; Ruehter, VL
    Atypical antipsychotic agents: A critical review
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    
    J.A. Worrel et al., "Atypical antipsychotic agents: A critical review", AM J HEAL S, 57(3), 2000, pp. 238-255
26. Feret, BM; Caley, CF
    Possible hypothyroidism associated with quetiapine
    ANNALS OF PHARMACOTHERAPY
    
    B.M. Feret e C.F. Caley, "Possible hypothyroidism associated with quetiapine", ANN PHARMAC, 34(4), 2000, pp. 483-486
27. Shelton, PS; Barnett, FL; Krick, SE
    Hyperventilation associated with quetiapine
    ANNALS OF PHARMACOTHERAPY
    
    P.S. Shelton et al., "Hyperventilation associated with quetiapine", ANN PHARMAC, 34(3), 2000, pp. 335-337
28. Davidson, M; Weiser, M; Soares, K
    Novel antipsychotics in the treatment of psychosis and aggression associated with dementia: A meta-analysis of randomized controlled clinical trials
    INTERNATIONAL PSYCHOGERIATRICS
    
    M. Davidson et al., "Novel antipsychotics in the treatment of psychosis and aggression associated with dementia: A meta-analysis of randomized controlled clinical trials", INT PSYCHOG, 12, 2000, pp. 271-277
29. Carriere, P; Bonhomme, D; Lemperiere, T
    Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)
    EUROPEAN PSYCHIATRY
    
    P. Carriere et al., "Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)", EUR PSYCHIA, 15(5), 2000, pp. 321-329
30. Balestrieri, M; Vampini, C; Bellantuono, C
    Efficacy and safety of novel antipsychotics: A critical review
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    
    M. Balestrieri et al., "Efficacy and safety of novel antipsychotics: A critical review", HUM PSYCHOP, 15(7), 2000, pp. 499-512
31. Thyrum, PT; Wong, YWJ; Yeh, C
    Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    
    P.T. Thyrum et al., "Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment", PROG NEUR-P, 24(4), 2000, pp. 521-533
32. Bogan, AM; Shellhorn, E; Brown, ES; Mcdanald, C; Suppes, T
    Switching outpatients between atypical antipsychotics
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    
    A.M. Bogan et al., "Switching outpatients between atypical antipsychotics", PROG NEUR-P, 24(2), 2000, pp. 351-355
33. Emsley, RA; Raniwalla, J; Bailey, PJ; Jones, AM
    A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    
    R.A. Emsley et al., "A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment", INT CLIN PS, 15(3), 2000, pp. 121-131
34. Vesely, C; Kufferle, B; Brucke, T; Kasper, S
    Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    
    C. Vesely et al., "Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine", INT CLIN PS, 15(1), 2000, pp. 57-60
35. Peuskens, J
    Switching approach in the management of schizophrenia patients
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    
    J. Peuskens, "Switching approach in the management of schizophrenia patients", INT CLIN PS, 15, 2000, pp. S15-S19
36. Guan, HJ; Dai, J; Zhu, XZ
    Atypical antipsychotic effects of quetiapine fumarate in animal models
    ACTA PHARMACOLOGICA SINICA
    
    H.J. Guan et al., "Atypical antipsychotic effects of quetiapine fumarate in animal models", ACT PHAR SI, 21(3), 2000, pp. 205-210
37. Barzega, G; Bogetto, F; Maina, G; Ravizza, L
    Quetiapine in schizophrenic patients: A high- and low-dose double-blind comparison
    EUROPEAN JOURNAL OF PSYCHIATRY
    
    G. Barzega et al., "Quetiapine in schizophrenic patients: A high- and low-dose double-blind comparison", EUR J PSYCH, 14(4), 2000, pp. 221-232
38. McConville, BJ; Arvanitis, LA; Thyrum, PT; Yeh, C; Wilkinson, LA; Chaney, RO; Foster, KD; Sorter, MT; Friedman, LM; Brown, KL; Heubi, JE
    Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders
    JOURNAL OF CLINICAL PSYCHIATRY
    
    B.J. McConville et al., "Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders", J CLIN PSY, 61(4), 2000, pp. 252-260
39. Garver, DL
    Review of quetiapine side effects
    JOURNAL OF CLINICAL PSYCHIATRY
    
    D.L. Garver, "Review of quetiapine side effects", J CLIN PSY, 61, 2000, pp. 31-33
40. Feifel, D
    Rationale and guidelines for the inpatient treatment of acute psychosis
    JOURNAL OF CLINICAL PSYCHIATRY
    
    D. Feifel, "Rationale and guidelines for the inpatient treatment of acute psychosis", J CLIN PSY, 61, 2000, pp. 27-32
41. Tariot, PN; Salzman, C; Yeung, PP; Pultz, J; Rak, IW
    Long-term use of quetiapine in elderly patients with psychotic disorders
    CLINICAL THERAPEUTICS
    
    P.N. Tariot et al., "Long-term use of quetiapine in elderly patients with psychotic disorders", CLIN THER, 22(9), 2000, pp. 1068-1084
42. Dev, V; Raniwalla, J
    Quetiapine - A review of its safety in the management of schizophrenia
    DRUG SAFETY
    
    V. Dev e J. Raniwalla, "Quetiapine - A review of its safety in the management of schizophrenia", DRUG SAFETY, 23(4), 2000, pp. 295-307
43. Yeung, PP; Tariot, PN; Schneider, LS; Salzman, C; Rak, IW
    Quetiapine for elderly patients with psychotic disorders
    PSYCHIATRIC ANNALS
    
    P.P. Yeung et al., "Quetiapine for elderly patients with psychotic disorders", PSYCHIAT AN, 30(3), 2000, pp. 197-201
44. Chakhava, VO
    Seroquel in patients with schizophrenia
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA
    
    V.O. Chakhava, "Seroquel in patients with schizophrenia", ZH NEVR PS, 100(9), 2000, pp. 63-64
45. Keltner, NL; Coffeen, H; Johnson, JE
    Atypical antipsychotic drugs: Part II
    PERSPECTIVES IN PSYCHIATRIC CARE
    
    N.L. Keltner et al., "Atypical antipsychotic drugs: Part II", PERSP PSY C, 36(4), 2000, pp. 139-141
46. Richard, IH; Nutt, J
    Worsening of motor function in Parkinson's disease - A "typical" response to "atypical" antipsychotic medications
    NEUROLOGY
    
    I.H. Richard e J. Nutt, "Worsening of motor function in Parkinson's disease - A "typical" response to "atypical" antipsychotic medications", NEUROLOGY, 55(6), 2000, pp. 748-749
47. Lambert, M; Moritz, S; Haasen, C; Naber, D
    Conversion from conventional to atypical neuroleptics - recommendations for inpatient and outpatient treatment
    NERVENARZT
    
    M. Lambert et al., "Conversion from conventional to atypical neuroleptics - recommendations for inpatient and outpatient treatment", NERVENARZT, 71(11), 2000, pp. 859
48. Schulz, SC
    New antipsychotic medications: More than old wine and new bottles
    BULLETIN OF THE MENNINGER CLINIC
    
    S.C. Schulz, "New antipsychotic medications: More than old wine and new bottles", B MENNINGER, 64(1), 2000, pp. 60-75
49. Taylor, DM; McAskill, R
    Atypical antipsychotics and weight gain - a systematic review
    ACTA PSYCHIATRICA SCANDINAVICA
    
    D.M. Taylor e R. McAskill, "Atypical antipsychotics and weight gain - a systematic review", ACT PSYC SC, 101(6), 2000, pp. 416-432
50. Vanhauwe, JFM; Ercken, M; van de Wiel, D; Jurzak, M; Leysen, JE
    Effects of recent and reference antipsychotic agents at human dopamine D-2and D-3 receptor signaling in Chinese hamster ovary cells
    PSYCHOPHARMACOLOGY
    
    J.F.M. Vanhauwe et al., "Effects of recent and reference antipsychotic agents at human dopamine D-2and D-3 receptor signaling in Chinese hamster ovary cells", PSYCHOPHAR, 150(4), 2000, pp. 383-390
51. Porter, JH; Varvel, SA; Vann, RE; Philibin, SD; Wise, LE
    Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats
    PSYCHOPHARMACOLOGY
    
    J.H. Porter et al., "Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats", PSYCHOPHAR, 149(2), 2000, pp. 189-193
52. Remington, G; Kapur, S
    Atypical antipsychotics: are some more atypical than others?
    PSYCHOPHARMACOLOGY
    
    G. Remington e S. Kapur, "Atypical antipsychotics: are some more atypical than others?", PSYCHOPHAR, 148(1), 2000, pp. 3-15
53. Duncan, GE; Zorn, S; Lieberman, JA
    Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
    MOLECULAR PSYCHIATRY
    
    G.E. Duncan et al., "Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia", MOL PSYCHI, 4(5), 1999, pp. 418-428
54. Canales, PL; Olsen, J; Miller, AL; Crismon, ML
    Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia
    CNS DRUGS
    
    P.L. Canales et al., "Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia", CNS DRUGS, 12(3), 1999, pp. 179-188
55. Prior, TI; Chue, PS; Tibbo, P; Baker, GB
    Drug metabolism and atypical antipsychotics
    EUROPEAN NEUROPSYCHOPHARMACOLOGY
    
    T.I. Prior et al., "Drug metabolism and atypical antipsychotics", EUR NEUROPS, 9(4), 1999, pp. 301-309
56. Stip, E; Lussier, I; Ngan, E; Mendrek, A; Liddle, P
    Discriminant cognitive factors in responder and non-responder patients with schizophrenia
    EUROPEAN PSYCHIATRY
    
    E. Stip et al., "Discriminant cognitive factors in responder and non-responder patients with schizophrenia", EUR PSYCHIA, 14(8), 1999, pp. 442-450
57. Leucht, S; Pitschel-Walz, G; Abraham, D; Kissling, W
    Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
    SCHIZOPHRENIA RESEARCH
    
    S. Leucht et al., "Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials", SCHIZOPHR R, 35(1), 1999, pp. 51-68
58. Keck, PE; McElroy, SL; Strakowski, SM
    Schizoaffective disorder: role of atypical antipsychotics
    SCHIZOPHRENIA RESEARCH
    
    P.E. Keck et al., "Schizoaffective disorder: role of atypical antipsychotics", SCHIZOPHR R, 35, 1999, pp. S5-S12
59. Volavka, J; Citrome, L
    Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns
    SCHIZOPHRENIA RESEARCH
    
    J. Volavka e L. Citrome, "Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns", SCHIZOPHR R, 35, 1999, pp. S23-S33
60. Purdon, SE
    Cognitive improvement in schizophrenia with novel antipsychotic medications
    SCHIZOPHRENIA RESEARCH
    
    S.E. Purdon, "Cognitive improvement in schizophrenia with novel antipsychotic medications", SCHIZOPHR R, 35, 1999, pp. S51-S60
61. Dickson, RA; Glazer, WM
    Neuroleptic-induced hyperprolactinemia
    SCHIZOPHRENIA RESEARCH
    
    R.A. Dickson e W.M. Glazer, "Neuroleptic-induced hyperprolactinemia", SCHIZOPHR R, 35, 1999, pp. S75-S86
62. Fernandez, HH; Friedman, JH; Jacques, C; Rosenfeld, M
    Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
    MOVEMENT DISORDERS
    
    H.H. Fernandez et al., "Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease", MOVEMENT D, 14(3), 1999, pp. 484-487
63. Hustey, FM
    Acute quetiapine poisoning
    JOURNAL OF EMERGENCY MEDICINE
    
    F.M. Hustey, "Acute quetiapine poisoning", J EMERG MED, 17(6), 1999, pp. 995-997
64. Davis, PC; Wong, J; Gefvert, O
    Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    
    P.C. Davis et al., "Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection", J PHARM B, 20(1-2), 1999, pp. 271-282
65. Dawkins, K; Lieberman, JA; Lebowitz, BD; Hsiao, JK
    Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998
    SCHIZOPHRENIA BULLETIN
    
    K. Dawkins et al., "Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998", SCHIZO BULL, 25(2), 1999, pp. 395-404
66. Campbell, M; Young, PI; Bateman, DN; Smith, JM; Thomas, SHL
    The use of atypical antipsychotics in the management of schizophrenia
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    M. Campbell et al., "The use of atypical antipsychotics in the management of schizophrenia", BR J CL PH, 47(1), 1999, pp. 13-22
67. Green, B
    Focus on quetiapine
    CURRENT MEDICAL RESEARCH AND OPINION
    
    B. Green, "Focus on quetiapine", CURR MED R, 15(3), 1999, pp. 145-151
68. Fleischhacker, WW; Hummer, M
    Do phase III trials have clinical value?
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    
    W.W. Fleischhacker e M. Hummer, "Do phase III trials have clinical value?", J CL PSYCH, 19(5), 1999, pp. 391-392
69. McManus, DQ; Arvanitis, LA; Kowalcyk, BB
    Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
    JOURNAL OF CLINICAL PSYCHIATRY
    
    D.Q. McManus et al., "Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders", J CLIN PSY, 60(5), 1999, pp. 292-298
70. Coley, KC; Carter, CS; DaPos, SV; Maxwell, R; Wilson, JW; Branch, RA
    Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol
    JOURNAL OF CLINICAL PSYCHIATRY
    
    K.C. Coley et al., "Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol", J CLIN PSY, 60(12), 1999, pp. 850-856
71. Tariot, PN
    Treatment of agitation in dementia
    JOURNAL OF CLINICAL PSYCHIATRY
    
    P.N. Tariot, "Treatment of agitation in dementia", J CLIN PSY, 60, 1999, pp. 11-20
72. Tandon, R; Milner, K; Jibson, MD
    Antipsychotics from theory to practice: Integrating clinical and basic data
    JOURNAL OF CLINICAL PSYCHIATRY
    
    R. Tandon et al., "Antipsychotics from theory to practice: Integrating clinical and basic data", J CLIN PSY, 60, 1999, pp. 21-28
73. Juncos, JL
    Management of psychotic aspects of Parkinson's disease
    JOURNAL OF CLINICAL PSYCHIATRY
    
    J.L. Juncos, "Management of psychotic aspects of Parkinson's disease", J CLIN PSY, 60, 1999, pp. 42-53
74. Kasper, S
    First-episode schizophrenia: The importance of early intervention and subjective tolerability
    JOURNAL OF CLINICAL PSYCHIATRY
    
    S. Kasper, "First-episode schizophrenia: The importance of early intervention and subjective tolerability", J CLIN PSY, 60, 1999, pp. 5-9
75. Gerlach, J
    The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment
    JOURNAL OF CLINICAL PSYCHIATRY
    
    J. Gerlach, "The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment", J CLIN PSY, 60, 1999, pp. 20-24
76. Tariot, PN
    The older patient: The ongoing challenge of efficacy and tolerability
    JOURNAL OF CLINICAL PSYCHIATRY
    
    P.N. Tariot, "The older patient: The ongoing challenge of efficacy and tolerability", J CLIN PSY, 60, 1999, pp. 29-33
77. Elliott, J; Reynolds, GP
    Agonist-stimulated GTP gamma[S-35] binding to 5-HT1A receptors in human post-mortem brain
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    J. Elliott e G.P. Reynolds, "Agonist-stimulated GTP gamma[S-35] binding to 5-HT1A receptors in human post-mortem brain", EUR J PHARM, 386(2-3), 1999, pp. 313-315
78. HAGBERG G; GEFVERT O; BERGSTROM M; WIESELGREN IM; LINDSTROM L; WIESEL FA; LANGSTROM B
    N-[C-11]METHYLSPIPERONE PET, IN CONTRAST TO [C-11] RACLOPRIDE, FAILS TO DETECT D-2 RECEPTOR OCCUPANCY BY AN ATYPICAL NEUROLEPTIC
    PSYCHIATRY RESEARCH-NEUROIMAGING
    
    G. Hagberg et al., "N-[C-11]METHYLSPIPERONE PET, IN CONTRAST TO [C-11] RACLOPRIDE, FAILS TO DETECT D-2 RECEPTOR OCCUPANCY BY AN ATYPICAL NEUROLEPTIC", PSYCHIATRY RESEARCH-NEUROIMAGING, 82(3), 1998, pp. 147-160
79. KING DJ
    QUETIAPINE - RESULTS OF 4 PHASE-II AND PHASE-III CLINICAL-TRIALS
    European psychiatry
    
    D.J. King, "QUETIAPINE - RESULTS OF 4 PHASE-II AND PHASE-III CLINICAL-TRIALS", European psychiatry, 13, 1998, pp. 15-21
80. HONG WW; RAK IW; CIURYLA VT; WILSON AM; KYLSTRA JW; MELTZER HY; CARPENTER WT; LEHMAN A; ARVANITIS LA
    MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION
    Schizophrenia research
    
    W.W. Hong et al., "MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION", Schizophrenia research, 32(1), 1998, pp. 51-58
81. GOREN JL; LEVIN GM
    QUETIAPINE, AN ATYPICAL ANTIPSYCHOTIC
    Pharmacotherapy
    
    J.L. Goren e G.M. Levin, "QUETIAPINE, AN ATYPICAL ANTIPSYCHOTIC", Pharmacotherapy, 18(6), 1998, pp. 1183-1194
82. BARNES TRE; MCPHILLIPS MA
    NOVEL ANTIPSYCHOTICS, EXTRAPYRAMIDAL SIDE-EFFECTS AND TARDIVE-DYSKINESIA
    International clinical psychopharmacology
    
    T.R.E. Barnes e M.A. Mcphillips, "NOVEL ANTIPSYCHOTICS, EXTRAPYRAMIDAL SIDE-EFFECTS AND TARDIVE-DYSKINESIA", International clinical psychopharmacology, 13, 1998, pp. 49-57
83. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
    CLINICAL DEVELOPMENT OF ATYPICAL ANTIPSYCHOTICS - RESEARCH DESIGN ANDEVALUATION
    The Journal of clinical psychiatry
    
    H.Y. Meltzer et al., "CLINICAL DEVELOPMENT OF ATYPICAL ANTIPSYCHOTICS - RESEARCH DESIGN ANDEVALUATION", The Journal of clinical psychiatry, 59, 1998, pp. 10-16
84. KING DJ; LINK CGG; KOWALCYK B
    A COMPARISON OF BD AND TID DOSE REGIMENS OF QUETIAPINE (SEROQUEL) IN THE TREATMENT OF SCHIZOPHRENIA
    Psychopharmacology
    
    D.J. King et al., "A COMPARISON OF BD AND TID DOSE REGIMENS OF QUETIAPINE (SEROQUEL) IN THE TREATMENT OF SCHIZOPHRENIA", Psychopharmacology, 137(2), 1998, pp. 139-146
85. GEFVERT O; BERGSTROM M; LANGSTROM B; LUNDBERG T; LINDSTROM L; YATES R
    TIME-COURSE OF CENTRAL NERVOUS DOPAMINE-D-2 AND 5-HT2 RECEPTOR BLOCKADE AND PLASMA DRUG CONCENTRATIONS AFTER DISCONTINUATION OF QUETIAPINE (SEROQUEL(R)) IN PATIENTS WITH SCHIZOPHRENIA
    Psychopharmacology
    
    O. Gefvert et al., "TIME-COURSE OF CENTRAL NERVOUS DOPAMINE-D-2 AND 5-HT2 RECEPTOR BLOCKADE AND PLASMA DRUG CONCENTRATIONS AFTER DISCONTINUATION OF QUETIAPINE (SEROQUEL(R)) IN PATIENTS WITH SCHIZOPHRENIA", Psychopharmacology, 135(2), 1998, pp. 119-126
86. ARVANITIS LA; MILLER BG; BORISON RL; PITTS WM; SHARIF ZA; HAMNER MB; HERZ MI; TRUE JE; VELLIGAN D; KNESEVICH MA; SMALL J; STEINBOOK R; HERTZMAN M; KECK PE; NEWCOMER JW; GRACE J; ROTROSEN J; TANDON R; DOTT SG; FERGUSON JM; ADDINGTON DEN; MACEWAN GW; NAIR VNP; SHRIQUI CL; WILLIAMS R; DANIEL DG; SHEHI GM; PATTERSON WM; MERIDETH CH
    MULTIPLE FIXED DOSES OF SEROQUEL (QUETIAPINE) IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA - A COMPARISON WITH HALOPERIDOL AND PLACEBO
    Biological psychiatry
    
    L.A. Arvanitis et al., "MULTIPLE FIXED DOSES OF SEROQUEL (QUETIAPINE) IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA - A COMPARISON WITH HALOPERIDOL AND PLACEBO", Biological psychiatry, 42(4), 1997, pp. 233-246
87. PEUSKENS J; LINK CGG
    A COMPARISON OF QUETIAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA
    Acta psychiatrica Scandinavica
    
    J. Peuskens e C.G.G. Link, "A COMPARISON OF QUETIAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA", Acta psychiatrica Scandinavica, 96(4), 1997, pp. 265-273
88. KUFFERLE B; TAUSCHER J; ASENBAUM S; VESELY C; PODREKA I; BRUCKE T; KASPER S
    IBZM SPECT IMAGING OF STRIATAL DOPAMINE-2 RECEPTORS IN PSYCHOTIC-PATIENTS TREATED WITH THE NOVEL ANTIPSYCHOTIC SUBSTANCE QUETIAPINE IN COMPARISON TO CLOZAPINE AND HALOPERIDOL
    Psychopharmacology
    
    B. Kufferle et al., "IBZM SPECT IMAGING OF STRIATAL DOPAMINE-2 RECEPTORS IN PSYCHOTIC-PATIENTS TREATED WITH THE NOVEL ANTIPSYCHOTIC SUBSTANCE QUETIAPINE IN COMPARISON TO CLOZAPINE AND HALOPERIDOL", Psychopharmacology, 133(4), 1997, pp. 323-328
89. TAUSCHER J; KUFFERLE B; ASENBAUM S; BRUCKE T; KASPER S
    PREVIOUS TREATMENT AS A CONFOUNDING VARIABLE IN STUDIES WITH NOVEL ANTIPSYCHOTICS - 2 CASES OF HIGH DOPAMINE-2 RECEPTOR OCCUPANCY WITH QUETIAPINE
    Psychopharmacology
    
    J. Tauscher et al., "PREVIOUS TREATMENT AS A CONFOUNDING VARIABLE IN STUDIES WITH NOVEL ANTIPSYCHOTICS - 2 CASES OF HIGH DOPAMINE-2 RECEPTOR OCCUPANCY WITH QUETIAPINE", Psychopharmacology, 133(1), 1997, pp. 102-105